No benefit of additional treatment with exenatide in patients with an acute myocardial infarction

International Journal of Cardiology

Volumn 220, Issue , 2016, Pages 809-814

  Roos, Sebastiaan T ^a,b   Timmers, Leo ^c   Biesbroek, Paul S ^a,b   Nijveldt, Robin ^a   Kamp, Otto ^a,b   van Rossum, Albert C ^a,b   van Hout, Gerardus P J ^c   Stella, Pieter R ^c   Doevendans, Pieter A ^c   Knaapen, Paul ^a   Velthuis, Birgitta K ^c   van Royen, Niels ^a   Voskuil, Michiel ^c   Nap, Alex ^a   Appelman, Yolande ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Coronary artery disease; Exenatide; Infarct size; Myocardial infarction

Indexed keywords

EXENDIN 4; PLACEBO; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; AGED; AGONISTS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FOLLOW UP; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; PROSPECTIVE STUDY; TRENDS;

AGED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOMS;

EID: 84977274730     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.283     Document Type: Article

References (23)

1. [1] Kolh, P., Wijns, W., Danchin, N., Di, M.C., Falk, V., Folliguet, T., et al. Guidelines on myocardial revascularization. Eur. J. Cardiothorac. Surg. 38:Suppl. (2010), S1–S52.
2. [2] Authors/Task Force members, Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., et al. ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35:2014 (2014), 2541–2619, 10.1093/eurheartj/ehu278.
3. [3] Yellon, D.M., Hausenloy, D.J., Myocardial reperfusion injury. N. Engl. J. Med. 357 (2007), 1221–1235, 10.1056/NEJMra071667.
4. [4] Roos, S.T., Juffermans, L.J.M., Slikkerveer, J., Unger, E.C., Porter, T.R., Kamp, O., Sonothrombolysis in acute stroke and myocardial infarction: a systematic review. IJC Heart Vessels 4 (2014), 1–6, 10.1016/j.ijchv.2014.08.003.
5. [5] Gersh, B.J., Stone, G.W., White, H.D., Holmes, D.R. Jr., Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. JAMA 293 (2005), 979–986.
6. [6] Bose, A.K., Mocanu, M.M., Carr, R.D., Brand, C.L., Yellon, D.M., Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005), 146–151.
7. [7] Nikolaidis, L.A., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965, 10.1161/01.CIR.0000120505.91348.58.
8. [8] Liu, Q., Anderson, C., Broyde, A., Polizzi, C., Fernandez, R., Baron, A., et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc. Diabetol., 9, 2010, 76, 10.1186/1475-2840-9-76.
9. [9] Bergenstal, R.M., Wysham, C., Macconell, L., Malloy, J., Walsh, B., Yan, P., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376 (2010), 431–439.
10. [10] Sonne, D.P., Engstrøm, T., Treiman, M., Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia–reperfusion injury in rat heart. Regul. Pept. 146 (2008), 243–249, 10.1016/j.regpep.2007.10.001.
11. [11] Timmers, L., Henriques, J.P., de Kleijn, D.P., Devries, J.H., Kemperman, H., Steendijk, P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53 (2009), 501–510.
12. [12] Lonborg, J., Vejlstrup, N., Kelbaek, H., Botker, H.E., Kim, W.Y., Mathiasen, A.B., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33 (2012), 1491–1499, 10.1093/eurheartj/ehr309.
13. [13] Woo, J.S., Kim, W., Ha, S.J., Kim, J.B., Kim, S.-J., Kim, W.-S., et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 2252–2260, 10.1161/ATVBAHA.113.301586.
14. [14] Bernink, F.J.P., Timmers, L., Beek, A.M., Diamant, M., Roos, S.T., Van Rossum, A.C., et al. Progression in attenuating myocardial reperfusion injury: an overview. Int. J. Cardiol. 170 (2014), 261–269, 10.1016/j.ijcard.2013.11.007.
15. [15] Scholte, M., Timmers, L., Bernink, F.J., Denham, R.N., Beek, A.M., Kamp, O., et al. Effect of additional treatment with EXenatide in patients with an acute myocardial infarction (EXAMI): study protocol for a randomized controlled trial. Trials, 12, 2011, 240, 10.1186/1745-6215-12-240.
16. [16] Bernink, F.J., Timmers, L., Diamant, M., Scholte, M., Beek, A.M., Kamp, O., et al. Effect of additional treatment with EXenatide in patients with an acute myocardial infarction: the EXAMI study. Int. J. Cardiol. 167 (2013), 289–290.
17. [17] Fuernau, G., Eitel, I., Franke, V., Hildebrandt, L., Meissner, J., De Waha, S., et al. Myocardium at risk in ST-segment elevation myocardial infarction. Jcmg. 4 (2011), 967–976, 10.1016/j.jcmg.2011.02.023.
18. [18] Versteylen, M.O., Bekkers, S.C.A.M., Smulders, M.W., Winkens, B., Mihl, C., Winkens, M.H.M., et al. Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction. Heart 98 (2012), 109–115, 10.1136/heartjnl-2011-300185.
19. [19] Stone, G.W., Maehara, A., Witzenbichler, B., Godlewski, J., Parise, H., Dambrink, J.-H.E., et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 307 (2012), 1817–1826, 10.1001/jama.2012.421.
20. [20] Lonborg, J., Kelbaek, H., Vejlstrup, N., Botker, H.E., Kim, W.Y., Holmvang, L., et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ. Cardiovasc. Interv. 5 (2012), 288–295, 10.1161/CIRCINTERVENTIONS.112.968388.
21. [21] Ritsinger, V., Malmberg, K., Martensson, A., Ryden, L., Wedel, H., Norhammar, A., Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised diabetes mellitus insulin glucose infusion in acute myocardial infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol. 2 (2014), 627–633.
22. [22] Fernández-Jiménez, R., Sánchez-González, J., Agüero, J., García-Prieto, J., López-Martín, G.J., García-Ruiz, J.M., et al. Myocardial edema after ischemia/reperfusion is not stable and follows a bimodal pattern. J. Am. Coll. Cardiol. 65 (2015), 315–323, 10.1016/j.jacc.2014.11.004.
23. [23] King, A.B., Wolfe, G., Healy, S., Clinical observations of exenatide treatment. Diabetes Care, 29, 2006, 1984.